Aura Bio gains after mid-stage data for lead asset in ocular cancer [Seeking Alpha]
Aura Biosciences, Inc. (AURA)
Company Research
Source: Seeking Alpha
control rate in a Phase 2 trial for patients with early-stage choroidal melanoma, a type of ocular cancer. The 22-patient open-label study also indicated that 90% of 10 Phase 3-eligible patients maintained visual acuity. Bel-sar, a virus-like particle conjugated with an anti-cancer agent, also demonstrated a favorable safety profile with no dose-limiting toxicities or treatment-related serious adverse events, according to Aura ( AURA “Bel-sar has the potential to become the first treatment that achieves the dual goals of treating the tumor while also preserving vision, which could change the treatment paradigm for patients with this disease,” said Ivana Kim, an associate professor of ophthalmology at Harvard Medical School. Patients are currently enrolling for the company's Phase 3 Compass trial for bel-sar in early-stage choroidal melanoma. More on Aura Biosciences Recommended For You More Trending News Recommended For You More Trending News About AURA Stock Rel
Show less
Read more
Impact Snapshot
Event Time:
AURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AURA alerts
High impacting Aura Biosciences, Inc. news events
Weekly update
A roundup of the hottest topics
AURA
News
- Sept. 13-20 Undercovered Stock Picks: Aura Biosciences, APA Corporation, iTeos, CuriosityStream + [Seeking Alpha]Seeking Alpha
- Aura Biosciences, Inc. (NASDAQ: AURA) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.MarketBeat
- Aura Stock Up as Lead Drug Shows Superior Efficacy in Eye Cancer Study [Yahoo! Finance]Yahoo! Finance
- Aura Biosciences, Inc. (NASDAQ: AURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $21.00 price target on the stock.MarketBeat
- Aura Biosciences, Inc. (NASDAQ: AURA) had its price target raised by analysts at JMP Securities from $19.00 to $23.00. They now have a "market outperform" rating on the stock.MarketBeat
AURA
Earnings
- 5/9/24 - Beat
AURA
Sec Filings
- 9/27/24 - Form 8-K
- 9/12/24 - Form 8-K
- 8/8/24 - Form 10-Q
- AURA's page on the SEC website